Xenon Pharmaceuticals Inc.
XENE
$58.76
-$0.79-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -110.74M | -102.30M | -105.26M | -90.90M | -84.71M |
| Total Depreciation and Amortization | 558.00K | 587.00K | 611.00K | 641.00K | 632.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.36M | 16.20M | 14.20M | 13.54M | 17.22M |
| Change in Net Operating Assets | 2.43M | -3.38M | 8.97M | 4.96M | 2.62M |
| Cash from Operations | -95.39M | -88.90M | -81.48M | -71.75M | -64.23M |
| Capital Expenditure | -275.00K | -133.00K | -318.00K | -281.00K | -157.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -330.96M | -407.15M | 63.02M | 38.81M | 82.42M |
| Cash from Investing | -331.24M | -407.28M | 62.70M | 38.53M | 82.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.00K | 843.01M | 113.54M | 2.36M | 65.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.00K | 843.01M | 113.54M | 2.36M | 65.00K |
| Foreign Exchange rate Adjustments | 262.00K | -130.00K | -104.00K | -6.00K | 632.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -426.34M | 346.70M | 94.65M | -30.87M | 18.72M |